Study design
systemic disease, Postoperative pain, communication difficulties, liver insufficiency, cognitive problems, allergic reactions
SYSTEMIC DISEASE, CHRONIC RENAL FAILURE, INFILTRATION, ALLERGIC REACTION, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, COAGULOPATHY, CHRONIC PAIN
This randomized, controlled study was registered with clinicaltrials.gov (ref: NCT05172882, first registration date was 29/12/2021) following local institutional review board of the Ethical Committee for Clinical Research of the Medical Faculty of Ataturk University, Erzurum, Turkey. The trial was conducted between November 2021 and April 2022. The study included ASA (American Society of Anesthesiology) Class I-II patients aged > 18y, and informed written consent was obtained. Patients with known allergic reactions to any of the study's drugs (bupivacaine and other analgesic drugs), severe systemic disease (chronic renal failure, liver insufficiency, chronic obstructive pulmonary disease, etc.), all chronic pains or history of analgesic use for long-duration or coagulopathy, patients with cognitive problems or unable to understand study protocol and communication difficulties, BMI greater than or equal to 30 and patients who refused participation in the study were excluded.Before the procedure, the patients were randomly assigned to one of two groups: TFPB group (Group TFPB) and surgical incision site infiltration group (group I) using a computer-generated randomization table. The patient study numbers and study group information were organized in two columns. The third column was created using the "RAND" function to randomly select the data in the first two columns. In this manner, patients were assigned to study groups in this column randomly. Postoperative pain evaluation was performed by a researcher who was not involved in the perioperative period of the study.